Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection

(E-pub Ahead of Print)

Author(s): Michele Costanzo, Maria Anna Rachele De Giglio, Giovanni N. Roviello*

Journal Name: Current Medicinal Chemistry

Become EABM
Become Reviewer
Call for Editor


The aim of this review article is to summarize the knowledge available to date on prophylaxis achievements in the frame of the fight against Coronaviruses. This work will give an overview of what is reported in the recent literature on vaccines (under investigation or already developed like BNT162b2, mRNA-1273, and ChAdOx1-S) effective against the most pathogenic Coronaviruses (SARS-CoV-1, MERS-CoV-1, and SARS-CoV-2), with of course particular attention paid to those under development or already in use to combat the current COVID-19 (CoronaVIrus Disease 19) pandemic. Our main objective is to make a contribution to the comprehension, even at a molecular level, of what is currently ready for anti-SARS-CoV-2 prophylactic intervention, as well as to provide the reader with an overall picture of the most innovative approaches for the development of vaccines that could be of general utility in the fight against the most pathogenic Coronaviruses.

Keywords: Coronavirus, coronavirus infections, pandemics, COVID-19, HCoV, SARS-CoV, SARS-CoV-2, MERS- CoV, vaccine, BioNTech/Pfizer, Moderna, Oxford/AstraZeneca, BNT162b2, mRNA-1273, ChAdOx1-S, Vaxzevria.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867328666210521164809

Article Metrics

PDF: 100